A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent, and EU-Dupixent in Healthy Adult Participants.

• Status: RECRUITING
• Trial end date: 2026-11-16

Summary

This is a randomised, double-blind, three-arm, parallel group, single-dose, Phase 1 comparative study of CKD-706, US-Dupixent, and EU-Dupixent in healthy adult participants.

• Phase: PHASE1

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical
• Collaborator: Parexel